- Report
- January 2022
- 40 Pages
United States
From €2506EUR$2,595USD£2,145GBP
- Report
- January 2022
- 80 Pages
Africa
From €3665EUR$3,795USD£3,137GBP
- Report
- January 2022
- 40 Pages
China
From €2506EUR$2,595USD£2,145GBP
- Report
- January 2022
- 40 Pages
France
From €2506EUR$2,595USD£2,145GBP
- Report
- January 2022
- 40 Pages
Ireland
From €2506EUR$2,595USD£2,145GBP
- Report
- January 2022
- 40 Pages
Japan
From €2506EUR$2,595USD£2,145GBP
- Report
- January 2022
- 40 Pages
Russia
From €2506EUR$2,595USD£2,145GBP
- Report
- January 2022
- 40 Pages
Vietnam
From €2506EUR$2,595USD£2,145GBP
- Report
- January 2022
- 40 Pages
Brazil
From €2506EUR$2,595USD£2,145GBP
- Report
- July 2022
- 274 Pages
Global
From €5621EUR$5,820USD£4,810GBP
- Report
- March 2022
- 225 Pages
Global
From €5572EUR$5,769USD£4,768GBP
The Colitis Drug market is a subset of the Gastrointestinal Drugs market, which includes drugs used to treat a variety of gastrointestinal disorders. Colitis drugs are used to treat inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. These drugs are typically administered orally or intravenously, and can include corticosteroids, immunomodulators, and biologics. Corticosteroids are used to reduce inflammation, while immunomodulators are used to suppress the immune system and reduce inflammation. Biologics are used to target specific proteins in the body that are involved in the inflammatory process.
Some companies in the Colitis Drug market include AbbVie, Amgen, AstraZeneca, Janssen, Merck, Pfizer, and Takeda. Show Less Read more